Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

54.98 -0.37 (-0.67%)

Streaming Delayed Price Updated: 2:45 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)

June 14, 2026

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Unpopular Stocks We’re Skeptical Of

June 12, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?

June 09, 2026

Royalty Pharma has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.3%, reaching $55.73 per share. This performan...

Via StockStory

Topics Supply Chain

Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean ↗

May 29, 2026

Mattel is a global toy and entertainment company behind brands like Barbie, Hot Wheels, and Fisher-Price, serving families worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum ↗

May 06, 2026

Via Chartmill

Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment ↗

March 27, 2026

Via Chartmill

ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗

March 18, 2026

Via Chartmill

Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 13, 2026

Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royal...

Via StockStory

Topics Earnings

Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗

May 10, 2026

Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales.

Via The Motley Fool

This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗

May 08, 2026

Preformed Line Products designs and manufactures network hardware for utilities and telecoms across global infrastructure markets.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat ↗

February 11, 2026

Via Chartmill

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗

May 06, 2026

Royalty Pharma (RPRX) Q1 2026 Earnings Transcript

Via The Motley Fool

Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

May 04, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. R...

Via StockStory

Topics Artificial Intelligence

3 Unpopular Stocks We’re Skeptical Of

April 22, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

April 10, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest

April 07, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Value Stock for Long-Term Investors and 2 Facing Challenges

April 03, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...

Via StockStory

1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm

March 31, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Topics Energy

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Topics Economy Initial Public Offering

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

March 25, 2026

Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. Th...

Via StockStory

Topics Artificial Intelligence Stocks Supply Chain

3 Healthcare Stocks Walking a Fine Line

February 18, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

Via StockStory

Topics Stocks

5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call

February 18, 2026

Royalty Pharma’s fourth quarter results did not meet Wall Street’s revenue or earnings expectations, with management attributing the performance to a combination of gradual product transitions in key...

Via StockStory

Topics Earnings

Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase ↗

February 14, 2026

Chime Financial delivers digital-first, fee-free banking solutions for U.S. consumers seeking accessible, low-cost financial services.

Via The Motley Fool

Royalty Pharma (RPRX) Q4 2025 Earnings Transcript ↗

February 11, 2026

Royalty Pharma (RPRX) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Bonds

Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

February 11, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 4.7% year on year to $622 million. Its GAAP profit of $0.64 per...

Via StockStory

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

February 09, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect.

Via StockStory

Topics World Trade

3 Mid-Cap Stocks We Keep Off Our Radar

February 05, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

3 Profitable Stocks with Open Questions

January 20, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.